SCHEMBL27094530

SCHEMBL27094530

CC[C@@H]1C[C@@H](CNC(=O)O)c2ncccc2O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPT P10636 2/20 0.37
▸ THRB P10828 2/20 0.37
▸ MTNR1A P48039 1/20 0.37
▸ MEN1 O00255 5/20 0.37
▸ KMT2A Q03164 5/20 0.37
▸ TP53 P04637 4/20 0.36
▸ AIMP2 Q13155 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ POLB P06746 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27094488 1.00 HTT (0.41) HTTGAATSHRL3MBTL1MAPT
SCHEMBL27094582 0.85 GAA (0.38) HTTGAATSHRL3MBTL1MAPT
SCHEMBL27094593 0.85 GAA (0.38) HTTGAATSHRL3MBTL1MAPT
SCHEMBL27094485 0.85 GAA (0.38) HTTGAATSHRL3MBTL1MAPT
SCHEMBL30030138 0.85 L3MBTL1 (0.41) HTTGAATSHRL3MBTL1MAPT
SCHEMBL30031883 0.85 L3MBTL1 (0.41) HTTGAATSHRL3MBTL1MAPT
SCHEMBL27094487 0.81 KDM4E (0.40) HTTGAATSHRL3MBTL1MEN1
SCHEMBL27094572 0.81 KDM4E (0.40) HTTGAATSHRL3MBTL1MEN1
SCHEMBL27094555 0.74 GAA (0.37) HTTGAATSHRL3MBTL1MEN1
SCHEMBL27094834 0.74 GAA (0.37) HTTGAATSHRL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-07-11 — — US disclosed
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-05-09 — — US disclosed
EP-4324834-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-02-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 HTT 4062/4885GAA 4693/4885TSHR 148/4885
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 HTT 4062/4885GAA 4693/4885TSHR 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback